RT-3: a synthesis of the research literature on the triple GLP-1/GIP/glucagon agonist
A triple GLP-1/GIP/glucagon agonist still in phase 3 clinical trials: editorial synthesis of what the published pharmacological literature documents on RT-3.
RT-3 is, to date, one of the most discussed molecules in the recent pharmacological literature on energy metabolism. This article offers an editorial synthesis of what the published scientific literature documents — without any usage claims or recommendations.
A triple-action molecular architecture
RT-3 differs from first-generation incretins through its triple agonist profile: the molecule is designed to bind to three distinct receptors involved in metabolic regulation:
- the GLP-1 (Glucagon-Like Peptide-1) receptor, already widely studied via molecules such as semaglutide;
- the GIP (Gastric Inhibitory Polypeptide) receptor, an incretin complementary to GLP-1;
- the glucagon receptor, involved in the regulation of hepatic energy expenditure.
This triple activity distinguishes it from dual agonists (GLP-1/GIP, such as tirzepatide) and is the subject of active comparative literature on the differential mechanisms of each receptor combination.
Origin and published clinical development
RT-3, referenced under the code LY3437943 in the pharmaceutical literature, was developed by a pharmaceutical company and is the subject of clinical trials, the phase 2 results of which have been published in peer-reviewed journals. These publications report pharmacokinetic data and metabolic parameters observed in trial participants — data that belongs to the public scientific literature and not to usage recommendations.
To date, the phase 3 clinical trial program is still ongoing. No marketing authorization has been granted in France, Europe, or the United States for this molecule.
What this means for research use
As long as no marketing authorization exists, RT-3 remains, by construction, a molecule exclusively available within a research setting — like thousands of compounds in development studied by academic laboratories before any potential market launch. It is within this strict framework that Peptinium Labs lists it: as a research reagent, documented by a Certificate of Analysis per batch, without any claim of therapeutic use.
Why triple activity interests comparative research
The pharmacological literature is particularly interested in the differential effects between single agonism (GLP-1 alone), dual agonism (GLP-1/GIP), and triple agonism (GLP-1/GIP/glucagon), in order to better understand the respective contribution of each signaling pathway to the metabolic parameters observed. RT-3 thus serves as a comparative research tool in this developing literature, alongside other agonists in development.
The analytical requirement remains the same
As with any research molecule, the value of a RT-3 sample depends entirely on its analytical documentation: HPLC purity ≥ 99%, mass confirmation by mass spectrometry, batch quantification. See our dedicated article on reading a CoA to understand what these controls guarantee — and what they do not.